Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2024
Reporting Period: Quarterly period ended June 30, 2024
This filing serves as a notification that the company issued a press release and an earnings presentation regarding its financial results for the quarter ended June 30, 2024. The detailed financial data is contained within the attached exhibits (Exhibit 99.1 and Exhibit 99.2) and is not embedded in the body of this 8-K form.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release and earnings presentation but are not disclosed within the text of this Form 8-K.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this filing. The document solely references the issuance of the Q2 2024 results.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that an earnings presentation was released on August 8, 2024, which likely contains management commentary, outlook, and guidance. However, the specific content of this presentation is not included in the text provided.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the body of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2024 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Earnings Presentation) for updated financial guidance, product pipeline milestones, and liquidity outlook.
- Verify the company's cash runway and burn rate as disclosed in the attached exhibits, given the absence of data in the 8-K summary.
- Check for any forward-looking statements regarding regulatory approvals or clinical trial results included in the presentation.